The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

September 30, 2028

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)

Injection, once, 6 months

DRUG

Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)

Injection, every two weeks for four doses, 6 months

Trial Locations (1)

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

INDUSTRY